Weight reduction associated with SGLT2i likely observed is mainly because of their glycosuria induced energy loss and reduction in the fat mass was found to be sustained for more than two years of treatment as reported by Bolinder J et al.22 Because of this weight reduction and improvement in BMI one can expect a decrease in daily dose requirement of insulin and SU as seen in this study and other clinical studies on this drug group.16, 18, 23 This decrease in insulin and SU further decreases the chances of weight gain and the risk of hypoglycemia associated with both of these agents. This evidence concerns the gene INS and Hypoglycemia.